Off-Label Compendia Weaknesses Illustrated By Tarceva Evidence Gaps

Compendia are often critical to reimbursement for oncology sponsors, but University of North Carolina researchers argue in JAMA the system needs to be revamped.

RollOfDollarswithPills_1200x675

Limitations in the evidence used by widely-consulted reference compendia to support off-label use of Roche/Astellas Pharma Inc.’s oncology drug Tarceva (erlotinib) demonstrate the weaknesses in the current system, researchers with the University of North Carolina Lineberger Comprehensive Cancer Center argue in an opinion piece published in the Journal of the American Medical Association Oct. 18.

The Medicare program and private payers have used third-party compendia to inform coverage decisions for off-label cancer drugs in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

More from Pink Sheet

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By 

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.

Report Shows Extent Of AI Use In EU Medicines Regulation During 2024

 

The AI observatory, created by the European medicines regulatory network to track the evolving use of artificial intelligence in medicines development and regulation, has issued its first annual report.

Prasad Cites Unproven Theory Defending His COVID-19 Vaccine Decisions

 

In defending his decision to overrule agency staff on three recent COVID-19 vaccine applications, the CBER director questioned the original timing of Pfizer’s COVID-19 vaccine authorization, reviving a long-held, but unproven grievance of President Trump.